Inactive Instrument

News Nightstar Therapeutics PLC

Equities

US65413A1016

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen	19-06-05	GL
Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen	19-05-29	GL
Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019	19-05-08	GL
Nightstar Therapeutics plc reaches agreement to be acquired by Biogen	19-03-04	GL
Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results	18-11-13	GL
Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference	18-10-04	GL
Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa	18-10-01	GL
Nightstar Announces Pricing of Public Offering	18-09-27	GL
Nightstar Announces Proposed Public Offering of American Depositary Shares	18-09-25	GL
Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of Directors	18-09-13	GL
Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights	18-08-13	GL
Nightstar Therapeutics to Present at Wedbush PacGrow Healthcare Conference	18-08-07	GL
Nightstar Therapeutics : Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia	18-06-14	GL
Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia	18-06-14	GL
Nightstar Therapeutics : Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018	18-06-06	GL
Nightstar Therapeutics : to Present at Jefferies 2018 Global Healthcare Conference	18-05-31	GL
Nightstar Therapeutics : to Present at the Deutsche Bank 43rd Annual Health Care Conference	18-04-30	GL
Nightstar Therapeutics : to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting	18-04-23	GL
Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights	18-04-03	GL
Nightstar Therapeutics : Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia	18-03-05	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nightstar Therapeutics PLC

Equities

US65413A1016

Summary

Filters